Cases with Refractory Ascites and a Delayed Response to Tolvaptan
Satoru Hagiwara1, Naoshi Nishida, Hirokazu Chishina
1Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan.
Internal Medicine (Tokyo, Japan)
|November 18, 2016
Summary
This case study shows that even with initially poor response, tolvaptan treatment for refractory ascites in liver cirrhosis patients can lead to significant fluid reduction over time. Continued therapy, despite mild symptoms, resulted in near-complete ascites resolution.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Ascites is a common complication of liver cirrhosis, significantly impacting patient quality of life.
- Diuretic resistance is frequently observed in patients with advanced liver disease, necessitating alternative treatment strategies.
Observation:
- A 67-year-old female with hepatitis C-induced liver cirrhosis presented with refractory ascites despite standard diuretic therapy (furosemide and spironolactone).
- Initial administration of tolvaptan at low doses (3.75 mg/day, then 7.5 mg/day) showed a poor response.
- The patient elected to continue tolvaptan 7.5 mg/day due to mild symptom progression and personal preference.
Findings:
- Despite initial poor response and persistent ascites, continued tolvaptan therapy led to near-complete resolution of ascites over 6 months, as confirmed by computed tomography (CT).
- This suggests a delayed or cumulative effect of tolvaptan in managing refractory ascites.
Implications:
- Tolvaptan may be a viable option for managing refractory ascites in select liver cirrhosis patients, even when initial responses are suboptimal.
- Patient preference and tolerance should be considered in long-term treatment decisions for chronic conditions.
- Further research into optimal dosing and treatment duration of tolvaptan for liver cirrhosis-related ascites is warranted.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
323
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
323
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
307
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
307
01:25Renal Drug Excretion: Tubular Reabsorption
1.0K
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
1.0K
01:28Renal Drug Excretion: Tubular Secretion
1.0K
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
1.0K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:11Renal Failure: Dose Adjustments
556
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
556